Our portfolio

CEPI is working to end pandemics by supporting the research and development of a diverse portfolio of vaccine candidates based on a range of vaccine approaches.

Explore our portfolio

CEPI funds the development of vaccine candidates against our priority pathogens and vaccine platforms to enable rapid development of vaccines against Disease X. Our interactive portfolio provides information on each of the vaccine candidates that CEPI has invested in. Filter information by developer, disease, phase of development, or vaccine type. You can also download a summary of our active portfolio.

Active portfolio summary

Portfolio: list view

Filter the portfolio
Developers
Disease
Phase
Vaccine type

Affinivax

Affinivax - Broadly Protective Coronavirus Vaccine

Vaccine type:
Multiple Antigen Presenting System technology
Funding:
Up to $4.5 million

CEPI supported the development of a vaccine candidate based on Affinivax’s innovative Multiple Antigen Presenting System (MAPSTM) technology.

The programme aimed to establish preclinical proof of concept for a vaccine candidate designed to protect against new COVID-19 variants suitable for use in the Global South.

CEPI funding has been discontinued.

Phase
  • Funding Discontinued
Tags
  • Multiple Antigen Presenting System technology
  • Coronavirus
  • Broadly protective coronavirus vaccine
  • COVID-19 variants

Akagera Medicines

Akagera - Disease X

Vaccine type:
Nucleic Acid
Funding:
Up to $1.5 million

CEPI is providing up to US $1.5 million to Akagera Medicines to demonstrate the pre-clinical proof of concept of their lipid nanoparticles (LNPs) and modified mRNA for the development of a multivalent influenza vaccine.

Their LNP formulation could optimise delivery of mRNA and reduce potential LNP-associated adverse events.

The technology could also improve the stability of the mRNA-based vaccines, removing the need for frozen storage to bolster equitable vaccine access.

Benefits could also include enhanced shelf life, reduced Cost of Goods, and a reduction in the required effective dose which would extend the number of doses that could be produced.

Phase
  • Preclinical
Tags
  • Disease X
  • MRNA

Auro vaccines & PATH

Auro Vaccines - Nipah

Vaccine type:
HeV-sG-V vaccine
Funding:
Up to $25 million

CEPI is providing up to US $25 million to advance development of the Nipah virus vaccine candidate, HeV-Sg-V.

HeV-sG-V Nipah is a recombinant subunit vaccine that contains a portion of the G glycoprotein of Hendra virus, a henipavirus closely related to Nipah.

HeV-sG-V became the first-ever Nipah vaccine candidate to enter in-human testing in 2020. The trial, sponsored by Auro Vaccines, investigated the safety, tolerability, and immunogenicity of the vaccine candidate.

PATH is leading clinical operations and CEPI is funding the programme through Phase 2 clinical trials. Under the terms of the original agreement awarded by CEPI, Emergent BioSolutions has provided contract development and manufacturing services to produce the Phase 1 clinical trial material. Through a separate agreement with Auro Vaccines, Emergent has an exclusive option to license and assume control of development activities for the Nipah virus vaccine candidate.

Phase
  • Phase 1
Tags
  • HeV-sG-V vaccine
  • Nipah

Bharat Biotech, University of Sydney, and ExcellGene

Bharat Biotech, University of Sydney, ExcellGene SA - Broadly Protective Coronavirus Vaccine

Vaccine type:
Modified Trimeric Spike
Funding:
Up to $19.3 million

CEPI is providing up to US$19.3 million to establish preclinical and clinical proof of concept for an adjuvanted subunit ‘variant-proof’ SARS-CoV-2 vaccine candidate being developed by an international consortium comprising Bharat Biotech International Ltd, University of Sydney and ExcellGene SA.

CEPI is funding the researchers to conduct activities including immunogen design, preclinical studies, manufacturing process development and a Phase 1 clinical trial.

The vaccine approach and scalable manufacturing process trialled as part of this project could also enable rapid development of broadly protective vaccines against other Betacoronaviruses, as well as vaccines against Disease X.

Phase
  • Preclinical
Tags
  • Modified Trimeric Spike
  • Broadly protective coronavirus vaccine
  • COVID-19 variants

BioNet

BioNet - Broadly Protective Coronavirus Vaccine

Vaccine type:
Nucleic Acid
Funding:
Up to $16.9 million

CEPI is providing up to US $16.9 million to BioNet to support preclinical studies, Phase I and Phase II clinical trials, production of necessary clinical trial material, and process and analytical development for a vaccine candidate that could provide broad protection against SARS-CoV-2 variants and other Betacoronaviruses.

BioNet are leading a global consortium of American and Thai universities and South Korea-based International Vaccine Institute to carry out the research.

Phase
  • Preclinical
Tags
  • Nucleic Acid
  • Broadly protective coronavirus vaccine
  • COVID-19 variants
Changed to page 1 of 13
1 of 13